IL183264A - Alpha thymosin peptides as cancer vaccine adjuvants - Google Patents

Alpha thymosin peptides as cancer vaccine adjuvants

Info

Publication number
IL183264A
IL183264A IL183264A IL18326407A IL183264A IL 183264 A IL183264 A IL 183264A IL 183264 A IL183264 A IL 183264A IL 18326407 A IL18326407 A IL 18326407A IL 183264 A IL183264 A IL 183264A
Authority
IL
Israel
Prior art keywords
cancer vaccine
vaccine adjuvants
alpha thymosin
thymosin peptides
peptides
Prior art date
Application number
IL183264A
Other languages
English (en)
Other versions
IL183264A0 (en
Inventor
Alfred R Rudolph
Gustavo Antonio Moviglia
Original Assignee
Sciclone Pharmaceuticals Inc
Alfred R Rudolph
Gustavo Antonio Moviglia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc, Alfred R Rudolph, Gustavo Antonio Moviglia filed Critical Sciclone Pharmaceuticals Inc
Publication of IL183264A0 publication Critical patent/IL183264A0/en
Publication of IL183264A publication Critical patent/IL183264A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL183264A 2004-12-06 2007-05-16 Alpha thymosin peptides as cancer vaccine adjuvants IL183264A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06
PCT/US2005/043985 WO2006062917A2 (en) 2004-12-06 2005-12-06 Alpha thymosin peptides as cancer vaccine adjuvants

Publications (2)

Publication Number Publication Date
IL183264A0 IL183264A0 (en) 2007-09-20
IL183264A true IL183264A (en) 2010-12-30

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
IL183264A IL183264A (en) 2004-12-06 2007-05-16 Alpha thymosin peptides as cancer vaccine adjuvants

Country Status (15)

Country Link
US (1) US20100092499A1 (cg-RX-API-DMAC7.html)
EP (1) EP1835931A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008523067A (cg-RX-API-DMAC7.html)
KR (1) KR20070086663A (cg-RX-API-DMAC7.html)
CN (1) CN101072582B (cg-RX-API-DMAC7.html)
AU (1) AU2005314271B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518571A2 (cg-RX-API-DMAC7.html)
CA (1) CA2588685A1 (cg-RX-API-DMAC7.html)
EA (1) EA015510B1 (cg-RX-API-DMAC7.html)
IL (1) IL183264A (cg-RX-API-DMAC7.html)
MX (1) MX2007006717A (cg-RX-API-DMAC7.html)
NO (1) NO20072705L (cg-RX-API-DMAC7.html)
NZ (1) NZ555571A (cg-RX-API-DMAC7.html)
UA (1) UA90493C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006062917A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506467A (ja) * 2007-12-14 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
CN104136040B (zh) * 2012-01-20 2021-05-25 费尔南多·托姆·克罗伊茨 自体癌细胞疫苗
US20150031617A1 (en) * 2012-03-08 2015-01-29 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for treatment of purulent rhinosinusitis
TWI683667B (zh) * 2014-10-21 2020-02-01 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
CZ20014718A3 (cs) * 1999-06-30 2003-01-15 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
DE60224435T2 (de) * 2001-10-26 2009-01-02 Rhode Island Hospital Thymosin-augmentation bei genetischer immunisierung
JP2005510491A (ja) * 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療
MXPA05000078A (es) * 2002-06-28 2005-04-11 Sciclone Pharmaceuticals Inc Metodo para sobre-regular la expresion de antigeno tumoral utilizando timalfasina, y composiciones y usos.
AU2004226403B2 (en) * 2003-03-28 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド

Also Published As

Publication number Publication date
AU2005314271A1 (en) 2006-06-15
UA90493C2 (ru) 2010-05-11
EP1835931A4 (en) 2008-12-17
KR20070086663A (ko) 2007-08-27
JP2008523067A (ja) 2008-07-03
WO2006062917A2 (en) 2006-06-15
US20100092499A1 (en) 2010-04-15
EA015510B1 (ru) 2011-08-30
WO2006062917A3 (en) 2006-11-16
CN101072582A (zh) 2007-11-14
EP1835931A2 (en) 2007-09-26
CA2588685A1 (en) 2006-06-15
MX2007006717A (es) 2007-08-06
CN101072582B (zh) 2012-06-27
EA200701166A1 (ru) 2008-02-28
NZ555571A (en) 2009-02-28
IL183264A0 (en) 2007-09-20
AU2005314271B2 (en) 2011-06-16
NO20072705L (no) 2007-09-05
BRPI0518571A2 (pt) 2008-11-25

Similar Documents

Publication Publication Date Title
IL183264A0 (en) Alpha thymosin peptides as cancer vaccine adjuvants
TWI365191B (en) Vaccine
ZA200804918B (en) Therapeutic vaccine
IL219040A (en) Peptide compounds derived from (cadherin3 (cdh3)
GB0419846D0 (en) Vaccine adjuvants for saccharides
ZA200705943B (en) Survivin peptide vaccine
GB0409940D0 (en) Vaccine
GB0329146D0 (en) Vaccine
GB0411150D0 (en) Vaccine
IL180839A0 (en) Vaccine comprising recombinant ct or lt toxin
AU2003264724A8 (en) Flagellin peptides as adjuvants for vaccines
EP1893233A4 (en) PEPTIDES AND THERAPEUTIC VACCINES
GB0427267D0 (en) Peptide adjuvants
AP2695A (en) Vaccine adjuvants
GB0305794D0 (en) Vaccine
GB0305793D0 (en) Vaccine
GB0413510D0 (en) Vaccine
IL178517A0 (en) Therapeutic peptides
ZA200800566B (en) Therapeutic peptides and vaccines
GB0526120D0 (en) Therapeutic peptides
GB0412407D0 (en) Vaccine
GB0308691D0 (en) Vaccine preparations
GB0428381D0 (en) Vaccine
GB0406598D0 (en) Vaccine
GB0419918D0 (en) Vaccine

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees